|
Market Closed -
Hong Kong S.E.
04:08:09 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 18.50 HKD | -1.18% |
|
-2.32% | -43.60% |
| 09-20 | VISEN Pharmaceuticals(SEHK:2561) dropped from S&P Global BMI Index | CI |
| 08-27 | VISEN Pharmaceuticals Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
Projected Income Statement: VISEN Pharmaceuticals
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Net sales 1 | - | 0.165 | 67.73 | 319.8 | 860.8 |
| Change | - | - | 40,951.3% | 372.15% | 169.15% |
| EBITDA 1 | - | -218 | -241.4 | -262.4 | -164.1 |
| Change | - | - | -10.73% | -8.7% | 37.47% |
| EBIT 1 | - | -208.6 | -245.7 | -264.3 | -166.2 |
| Change | - | - | -17.77% | -7.58% | 37.13% |
| Interest Paid | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -253.4 | - | - | - |
| Change | - | - | - | - | - |
| Net income | -182.2 | -253.4 | - | - | - |
| Change | - | -39.06% | - | - | - |
| Announcement Date | 4/30/25 | 3/12/26 | - | - | - |
1CNY in Million
Estimates
Forecast Balance Sheet: VISEN Pharmaceuticals
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Net Debt 1 | - | -456 | -262 | 0.49 | 140 |
| Change | - | - | 42.5% | 100.19% | 28,471.43% |
| Announcement Date | 4/30/25 | 3/12/26 | - | - | - |
1CNY in Million
Estimates
Cash Flow Forecast: VISEN Pharmaceuticals
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| CAPEX 1 | 1.484 | 0.52 | 0.117 | 1.489 |
| Change | - | -64.96% | -77.5% | 1,172.65% |
| Free Cash Flow (FCF) 1 | - | -67.66 | -63.57 | -366.7 |
| Change | - | - | 6.05% | -476.91% |
| Announcement Date | 9/26/24 | 9/26/24 | 4/30/25 | 4/28/26 |
1CNY in Million
Estimates
Forecast Financial Ratios: VISEN Pharmaceuticals
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
Profitability | |||||
| EBITDA Margin (%) | - | -132,104.24% | -356.34% | -82.04% | -19.06% |
| EBIT Margin (%) | - | -126,427.27% | -362.7% | -82.64% | -19.3% |
| EBT Margin (%) | - | -153,589.09% | - | - | - |
| Net margin (%) | - | -153,589.09% | - | - | - |
| FCF margin (%) | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - |
Profitability | |||||
| ROA | - | -39.87% | - | - | - |
| ROE | - | -50.52% | -37.65% | -67.25% | -79.02% |
Financial Health | |||||
| Leverage (Debt/EBITDA) | - | - | - | -0x | -0.85x |
| Debt / Free cash flow | - | - | - | - | - |
Capital Intensity | |||||
| CAPEX / Current Assets (%) | - | 902.42% | - | - | - |
| CAPEX / EBITDA (%) | - | -0.68% | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - |
Items per share | |||||
| Cash flow per share 1 | - | - | - | - | - |
| Change | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - |
| Change | - | - | - | - | - |
| Book Value Per Share 1 | - | 6.989 | 4.57 | 2.27 | 0.98 |
| Change | - | - | -34.61% | -50.33% | -56.83% |
| EPS 1 | -1.95 | -2.44 | - | - | - |
| Change | - | -25.13% | - | - | - |
| Nbr of stocks (in thousands) | - | 105,021 | 109,295 | 109,295 | 109,295 |
| Announcement Date | 4/30/25 | 3/12/26 | - | - | - |
1CNY
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | - | - |
| PBR | 3.46x | 6.96x |
| EV / Sales | 21.6x | 5.4x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
15.81CNY
Average target price
42.85CNY
Spread / Average Target
+171.08%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2561 Stock
- Financials VISEN Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
